*3.3.4 Conclusions/future directions*

Activating and optimizing the body's own immune system is at the core of precision medicine. Pathologic review showed evidence of **enhanced immune cell trafficking in the tumor microenvironment of patients treated with DeltaRex-G, suggesting that this treatment activates the innate immune response**. This implies that DeltaRex-G may enhance the performance of an immunotherapy agent when used simultaneously. Three patients identified in the literature with metastatic pancreatic cancer, B-cell lymphoma and metastatic osteosarcoma, respectively, have survived over 10 years following treatment with DeltaRex-G, no cancers have recurred, and no additional treatments have been needed. This clinical evidence strongly suggests that **DeltaRex-G has the ability to promote cancer immunization in situ through CCNG1 inhibition without causing deleterious immune suppression** [9]. Therefore, further evaluation of the role of DeltaRex-G in enhancing immune cell trafficking in the tumor microenvironment is warranted.
